Pryor Cashman represented ROTH Capital Partners as sole placement agent in connection with their $13.5 million public offering of common stock by Bio-Path Holdings, Inc., a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. According to the press release:

Bio-Path Holdings, Inc., (Nasdaq: BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the pricing of its previously announced public offering for the offering of 1,710,600 shares of common stock at a price to the public of $7.60 per share, for aggregate gross proceeds to the Company of approximately $13.0 million, before deducting the fees and estimated offering expenses payable by the Company. 

The Pryor Cashman team was led by partner Ali Panjwani, co-chair of the Corporate Group. 

Read the full press release announcement in the link below.